Tenofovir Alafenamide
Generic Details
Generic Name
Tenofovir-Alafenamide
Other Names
- TAF
Drug Class
- Antiretroviral
Chemical Formula
C21H29N6O5P
Molecular Weight
476.47 g/mol
Mechanism of Action
- Tenofovir-Alafenamide is a prodrug of tenofovir, which inhibits the activity of HIV reverse transcriptase by competing with the natural substrate deoxyadenosine 5′-triphosphate, leading to chain termination.
Indications
- HIV-1 infection
- Chronic hepatitis B
Common Dosage Forms
- Tablet
- Oral solution
Typical Dosage
- One tablet (25 mg) once daily with food for HIV-1 infection
- One tablet (25 mg) once daily for chronic hepatitis B
Pediatric Dosage
- Dosage varies based on weight and age, consulting a healthcare provider is recommended
Geriatric Dosage
- No specific dosage adjustment is required based on age alone; however, renal function should be monitored
Side Effects
- Nausea
- Diarrhea
- Headache
- Fatigue
- Elevations in blood creatinine
Contraindications
- Hypersensitivity to Tenofovir-Alafenamide
Pregnancy Category
- Category B - Animal reproduction studies have failed to demonstrate a risk to the fetus and there are no adequate and well-controlled studies in pregnant women
Lactation Safety
- Limited data suggests minimal risk while breastfeeding, monitor the infant for gastrointestinal disturbances
Drug Interactions
- Tenofovir-Alafenamide may interact with drugs that affect renal function or are nephrotoxic, such as NSAIDs or certain antibiotics
Overdose Symptoms
- Acute renal failure
- Fanconi syndrome
Antidote for Overdose
- There is no specific antidote, treatment is supportive and based on symptoms
Storage Conditions
- Store at room temperature between 20-25°C (68-77°F)
- Protect from light and moisture
Pharmacokinetics
- Absorption: Well absorbed following oral administration
- Distribution: Distributed to plasma and peripheral blood mononuclear cells
- Metabolism: Metabolized in the liver to tenofovir
- Excretion: Primarily excreted in the urine
Precautions
- Monitor renal function regularly, especially in patients with preexisting renal impairment
Warnings
- May cause renal impairment, osteomalacia, and exacerbation of hepatitis B upon discontinuation
Others
- Tenofovir-Alafenamide has demonstrated similar efficacy to tenofovir disoproxil fumarate but with lower renal and bone toxicity